Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pi Kang Wang
- Development stage
- Unknown
- Lead developer
- Dihon Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Pi Kang Wang is an over-the-counter (OTC) dermatology product rooted in Traditional Chinese Medicine (TCM). It is primarily indicated for the treatment of dandruff and scalp disorders. Originally developed by Dihon Pharmaceutical Group, a Chinese company specializing in OTC and TCM products, it became part of Bayer's Consumer Care portfolio following Bayer's acquisition of Dihon in November 2014. The acquisition aimed to strengthen Bayer's presence in the Chinese OTC market and potentially expand Dihon's products, including Pi Kang Wang, internationally.
- Brand names
- Pi Kang Wang
Beyond the preview
Go deeper on Pi Kang Wang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pi Kang Wang.